Table 3. Patient characteristics of... | American Society of Hematology

Table 3.

Patient characteristics of complementary cohort depending on BU stage

	Stage I (n = 151)	Stage II (n = 259)	Stage III (n = 182)
General characteristics
Age	59 (52-67)	63 (54-68)*	62 (56-68)*
Male, n (%)	83 (55)	154 (60)	124 (68)*
Treatment
HDM/SCT, n (%)	56 (37)	67 (26)*	26 (14)**^,†
Proteasome inhibitor, n (%)	48 (32)	92 (36)	63 (35)
Immunomodulatory agent, n (%)	14 (9)	35 (14)	18 (10)
Alkylators, n (%)	4 (2)	19 (7)*	22 (12)*
Laboratory data
BNP, pg/mL	36 (23-57)	210 (130-410)**	719 (394-1401)**^,††
Troponin I, ng/mL	0.011 (0.006-0.020)	0.035 (0.018-0.062)**	0.218 (0.138-0.399)**^,††
eGFR, mL/min/1.73 m²	84 (54-99)	64 (39-87)**	56 (33-80)**^,†
Transthoracic echocardiography	(n=136)	(n=242)	(n=174)
IVSd, mm	10 (8-12)	12 (10-14)**	14 (12-16)**^,††
Ejection fraction, %	64 (60-65)	61 (55-65)**	52 (41-60)**^,††

	Stage I (n = 151)	Stage II (n = 259)	Stage III (n = 182)
General characteristics
Age	59 (52-67)	63 (54-68)*	62 (56-68)*
Male, n (%)	83 (55)	154 (60)	124 (68)*
Treatment
HDM/SCT, n (%)	56 (37)	67 (26)*	26 (14)**^,†
Proteasome inhibitor, n (%)	48 (32)	92 (36)	63 (35)
Immunomodulatory agent, n (%)	14 (9)	35 (14)	18 (10)
Alkylators, n (%)	4 (2)	19 (7)*	22 (12)*
Laboratory data
BNP, pg/mL	36 (23-57)	210 (130-410)**	719 (394-1401)**^,††
Troponin I, ng/mL	0.011 (0.006-0.020)	0.035 (0.018-0.062)**	0.218 (0.138-0.399)**^,††
eGFR, mL/min/1.73 m²	84 (54-99)	64 (39-87)**	56 (33-80)**^,†
Transthoracic echocardiography	(n=136)	(n=242)	(n=174)
IVSd, mm	10 (8-12)	12 (10-14)**	14 (12-16)**^,††
Ejection fraction, %	64 (60-65)	61 (55-65)**	52 (41-60)**^,††

All values presented as median (25-75%) unless otherwise specified.

HDM/SCT, high-dose melphalan and stem cell transplantation.

P value compared with stage I is <.05.

P value compared with stage I is <.001.

P value compared with stage II is <.05.

P value compared with stage II is <.001.